Choose a language and wait for the translated text.
Shots:
Ensem Therapeutics has dosed the first patients in its first-in-human P-I/II trial of ETX-929, an oral pan-KRAS inhibitor, in advanced solid tumors with KRAS alterations, including colorectal, pancreatic, NSCLC and gynecologic cancers
The open-label, multicenter dose-escalation and expansion study will assess the safety, tolerability, PK, PD and preliminary antitumor activity of ETX-929 as monotherapy and in combination with cetuximab, under an FDA-cleared IND (NCT07912593)
ETX-929 inhibits KRAS in both its active (ON) and inactive (OFF) states while sparing HRAS and NRAS, and is the third clinical candidate from the companyβs Kinetic Ensemble platform after ETX-197 and ETX-636
Ref: Business Wire | Image: Ensem Therapeutics | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
The post Ensem Therapeutics Doses First Patients in the P-I/II Trial of ETX-929 for KRAS-Altered Advanced Solid Tumors appeared first on PharmaShots.
Ensem Therapeutics Doses First Patients in the P-I/II Trial of ETX-929 for KRAS-Altered Advanced Solid Tumors | PharmaVoice